



Attention BCN Advantage Group members:

This is a list of changes made to the BCN Advantage Group Formulary since its initial release in October 2023

BCN Advantage may add or remove drugs from our formulary during the year. If we make any of the following changes, we'll notify you of the change at least 30 days before the effective date:

- Remove drugs from our formulary
- Add prior authorization, quantity limits and/or step therapy to a drug
- Move the drug to a higher cost-sharing tier

Some formulary changes don't require advance notice but will be posted on this [link](#). If your physician prescribes a drug that isn't on our formulary, isn't a preferred drug, or is subject to additional utilization requirements, you can ask us to make a coverage exception. You or your physician can initiate an exception request. While the use of a form isn't always required, they're available on the BCNA website at www.bcbsm.com/medicare.

Coverage determinations will be made for standard and urgent requests within 72 and 24 hours, respectively. If BCN Advantage ever denies coverage for your prescription drugs, we'll explain our decision. You always have the right to appeal and ask us to review a claim denial. For more detailed information about your BCN Advantage prescription drug coverage, review your BCN Advantage Group *Formulary* or *Evidence of Coverage*.

If you have questions about the BCN Advantage drug formularies, call Customer Service at 1-800-450-3680. Hours are from 8 a.m. to 8 p.m. Eastern time, Monday through Friday. From October 1 through March 31, hours are from 8 a.m. to 8 p.m. Eastern time, seven days a week. TTY users call 711.

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)**
Most recent changes appear at the beginning

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
5/1/2024	FLUTICASONE PROPIONATE HFA 44MCG/ACT, 110MCG/ACT, 220MCG/ACT INHALATION		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3 with Quantity Limits
5/1/2024	FLUTICASONE PROPIONATE DISKUS 50MCG/ACT, 100MCG/ACT, 250MCG/ACT INHALATION		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3 with Quantity Limits
5/1/2024		heather 0.35mg oral tablet	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 2
5/1/2024	IXCHIQ INJECTION		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3
5/1/2024	JOENJA 70MG ORAL TABLET		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)**
Most recent changes appear at the beginning

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
5/1/2024		mifepristone 300mg oral tablet	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization
5/1/2024	MOTPOLY XR 150MG, 200MG EXTENDED RELEASE ORAL CAPSULE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
5/1/2024	RIVFLOZA 80MG/0.5ML INJECTION		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
5/1/2024	RIVFLOZA 128MG/0.8ML, 160MG/ML PREFILLED SYRINGE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
5/1/2024	ROZLYTREK 50MG ORAL PELLETT		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)
Most recent changes appear at the beginning**

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
5/1/2024	TERIPARATIDE 620MCG/2.48ML INJECTION		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
5/1/2024	TRIENTINE HYDROCHLORIDE 500MG ORAL CAPSULE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5
5/1/2024	XOLAIR 75MG/0.5ML, 150MG/ML, 300MG/2ML AUTO INJECTOR		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization
5/1/2024	XOLAIR 300MG/2ML PREFILLED SYRINGE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)**
Most recent changes appear at the beginning

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
4/1/2024	BOSULIF 50MG, 100MG ORAL CAPSULE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
4/1/2024	FLURAZEPAM HCL 15MG, 30MG ORAL CAPSULE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 4
4/1/2024	IWILFIN 192MG ORAL TABLET		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
4/1/2024	PENBRAYA 0.5ML INJECTION		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3
4/1/2024		risperidone er 12.5mg injection	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 4 with Step Therapy

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)**
Most recent changes appear at the beginning

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
4/1/2024		risperidone er 25mg, 37.5mg, 50mg injection	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Step Therapy
4/1/2024		sodium sulfate/potassium sulfate/magnesium sulfate 1.6gm/177ml; 3.13gm/177ml; 17.5gm/177ml oral solution	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3
4/1/2024	SYNJARDY XR 5MG/1000MG, 10MG/1000MG, 12.5MG/1000MG, 25MG/1000MG EXTENDED-RELEASE ORAL TABLET		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3 with Quantity Limits
4/1/2024	XALKORI 20MG, 50MG, 150MG ORAL CAPSULE SPRINKLE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
4/1/2024	ZILBRYSQ 23MG/0.574ML, 32.4MG/0.81ML		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization and Quantity Limits

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)**
Most recent changes appear at the beginning

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
3/1/2024	AKEEGA 500MG/50MG, 500MG/100MG ORAL TABLET		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
3/1/2024	AUGTYRO 40MG ORAL CAPSULE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
3/1/2024		ethinyl estradiol/norelgestromin 35mcg/24hr; 150mcg/24hr transdermal system	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 2
3/1/2024	KALYDECO 5.8 MG ORAL GRANULES		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization
3/1/2024	OGSIVEO 50MG ORAL TABLET		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary
(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)**
Most recent changes appear at the beginning

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
3/1/2024	ZENPEP 252,600/60,000/189,600 UNITS DELAYED RELEASE ORAL CAPSULE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)**
Most recent changes appear at the beginning

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
2/1/2024	BREO ELLIPTA 50MCG/INH; 25MCG/INH AEROSOL POWDER BREATH ACTIVATED		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3 with Quantity Limits
2/1/2024		brimonidine tartrate 0.1% ophthalmic solution	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3
2/1/2024		enilloring 0.015mg/24hr; 0.12mg/24hr vaginal ring	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 4
2/1/2024	FRUZAQLA 1MG, 5MG ORAL CAPSULE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
2/1/2024		glipizide 2.5mg oral tablet	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 2 with Quantity Limits

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)
Most recent changes appear at the beginning**

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
2/1/2024		kourzeq 0.1% dental paste	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 2
2/1/2024	LAGEVRIO 200MG ORAL CAPSULE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3 with Quantity Limits
2/1/2024		lithium 8meq/5ml oral solution	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 1
2/1/2024	OJJAARA 100MG, 150MG, 200MG ORAL TABLET		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
2/1/2024	OPVEE 2.7MG/0.1ML NASAL SPRAY		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3 with Quantity Limits

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)**
Most recent changes appear at the beginning

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
2/1/2024	PAXLOVID 150MG; 100MG ORAL TABLET PACK		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 3 with Quantity Limits
2/1/2024		pazopanib hydrochloride 200mg oral tablet	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization
2/1/2024		phenytek 200mg, 300mg oral capsule	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 2
2/1/2024		pitavastatin calcium 1mg, 2mg, 4mg oral tablet	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 1 with Quantity Limits
2/1/2024	SOHONOS 1MG, 1.5MG, 2.5MG, 5MG, 10MG ORAL CAPSULE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)**
Most recent changes appear at the beginning

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
2/1/2024	TRUQAP 160MG, 200MG ORAL TABLET		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
2/1/2024		turqoz 30mcg; 0.3mg oral tablet	Addition to Formulary	General Formulary Maintenance	Drug is on Tier 2
2/1/2024	VANFLYTA 17.7MG, 26.5MG ORAL TABLET		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
2/1/2024	XDEMVA 0.25% OPHTHALMIC SOLUTION		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits
2/1/2024	ZURZUVAE 20MG, 25MG, 30MG ORAL CAPSULE		Addition to Formulary	General Formulary Maintenance	Drug is on Tier 5 with Prior Authorization & Quantity Limits

BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary

(Updated 5/1/2024)

**Changes made to the drugs in the BCN Advantage HMO-POS
Group Comprehensive Formulary (additions, deletions, changes in coverage)**
Most recent changes appear at the beginning

Effective Date	Brand Name	Generic Name	Type of Change	Reason for Change	Notes
2/1/2024		budesonide 0.25mg/2ml, 0.5mg/2ml, 1mg/2ml inhalation suspension	Tier Decrease	General Formulary Maintenance	Drug is on Tier 3 with BvsD Prior Authorization